Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Gastrointestinal 1

Conditions

Neoplasms 1Gastrointestinal Neoplasms 1Extensive Stage Lung Small Cell Carcinoma 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 223Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × LB100 × Clear all
NCT04560972 2026-04-07

LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer

City of Hope Medical Center

Phase 1 Active not recruiting
3 enrolled

Extensive Stage Lung Small Cell Carcinoma

NCT06012734 2024-08-30

CoLBAt

The Netherlands Cancer Institute

Phase 1 Recruiting
37 enrolled
Gastrointestinal

Gastrointestinal Neoplasms, Colorectal Neoplasms

NCT01837667 2017-01-24

Phase I Study of LB-100 With Docetaxel in Solid Tumors

Lixte Biotechnology Holdings, Inc.

Phase 1 Completed
29 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡